Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Status: open

17-316 - CX-1158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Treatment for Lung Cancer

Contact Us Or call (251) 445-9834

Description

This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. IRB Number 17-316

Sponsors

This trial is sponsored by Incyte Corporation.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.